Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Timothy M. Browder, Catherine Butterfield, Birgit M. Kräling et al. · PubMed · 2000 · 1.6K citations

Medicine, Oncology, Pharmacology +16

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

François Ghiringhelli, Cédric Menard, Pierre E. Puig et al. · Cancer Immunology Immunotherapy · 2006 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Giannoula Klement, Sylvain Baruchel, Janusz Rak et al. · Journal of Clinical Investigation · 2000 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +11

Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer

Pedro M. Enríquez‐Navas, Yoonseok Kam, Tuhin K. Das et al. · Science Translational Medicine · 2016 · 334 citations

Medicine, Oncology, Pharmacology +12

Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.

Giannoula Klement, Ping Huang, Barbara Mayer et al. · PubMed · 2002 · 246 citations

Medicine, Oncology, Pharmacology +14